Umbilical cord blood is an alternative hematopoietic stem cell source for patients with
hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation …

Unrelated donor cord blood transplantation (CBT) results in disease-free survival
comparable to that of unrelated adult donor transplantation in patients with hematologic …

We studied the effect of allele-level matching at human leukocyte antigen (HLA)-A,-B,-C, and-
DRB1 in 1568 single umbilical cord blood (UCB) transplantations for hematologic …

Cell dose is a major limitation for umbilical cord blood (UCB) transplantation because units
containing a minimum of 2.5× 107 total nucleated cells (TNC)/kilogram patient body weight …

Using a uniform detection method for donor-specific anti-HLA antibodies (DSAs), we sought
to determine the effect of preformed DSAs on outcomes in double umbilical cord blood …

Only 30% of patients who require an allogeneic hematopoietic cell transplant will have an
HLA-matched sibling donor. A search for an unrelated donor will be undertaken for patients …

Allogeneic hematopoietic cell transplantation (HCT) provides the best chance for cure for
many patients with malignant and nonmalignant hematologic disorders. Recent advances in …

Optimal cord blood (CB) unit selection is critical to maximize the likelihood of successful
engraftment and survival after CB transplantation (CBT). However, unit selection can be …

While cord blood transplantation (CBT) is an effective therapy for hematologic malignancies,
acute graft-versus-host disease (aGVHD) is a leading cause of transplant-related mortality …

Abstract Availability of 8/8 HLA-allele matched unrelated donors (URDs) is a barrier for
ethnic and racial minorities. We prospectively evaluated receipt of 8/8 HLA-allele matched …